Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Baxter
Teva
Citi
AstraZeneca
Accenture
Boehringer Ingelheim
Fuji
Merck
Medtronic

Generated: August 20, 2017

DrugPatentWatch Database Preview

TOTECT Drug Profile

« Back to Dashboard

Which patents cover Totect, and what generic Totect alternatives are available?

Totect is a drug marketed by Clinigen Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in sixteen countries.

The generic ingredient in TOTECT is dexrazoxane hydrochloride. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the dexrazoxane hydrochloride profile page.

Summary for Tradename: TOTECT

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list84
Clinical Trials: see list2
Patent Applications: see list131
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:TOTECT at DailyMed

Pharmacology for Tradename: TOTECT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Clinigen Hlthcare
TOTECT
dexrazoxane hydrochloride
INJECTABLE;INJECTION022025-001Sep 6, 2007RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: TOTECT

Country Document Number Estimated Expiration
Germany60010241► Subscribe
Hong Kong1043054► Subscribe
European Patent Office1162981► Subscribe
China1346275► Subscribe
World Intellectual Property Organization (WIPO)0054782► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
AstraZeneca
Medtronic
Chubb
Deloitte
Fish and Richardson
McKesson
Johnson and Johnson
QuintilesIMS
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot